Drugs / N-803
N-803
English name Anktiva
also known as
ALT-803 · nogapendekin alfa inbakicept · IL-15 · NAI · ANKTIVA · rhIL-15 · IL-15N72D:IL-15RαSu/IgG1 Fc complex · Interleukin-15 · +3 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved · conditional | EU (EMA) | Anktiva | — | 2026-02-16 | europa.eu ↗ |
| Approved | US (FDA) | ANKTIVA | — | 2024-04-22 | fda.gov ↗ |
Trials 95 · started per year
today
US approved 2024
EU approved 2026
1
2
1
4
4
2
17
15
1
7
6
1
3
5
10
15
200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07261657 | Apr 2026 → Sep 2030 expected | myxoid liposarcoma, round cell liposarcoma, synovial sarcoma | Seth Pollack | Recruiting | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT07488884 | Jun 2026 → Jun 2027 expected | pancreatic ductal adenocarcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07217496 | Feb 2026 → May 2027 | urothelial carcinoma | Vadim S Koshkin | Withdrawn | No outcome recorded |
| Phase 1 | NCT07049432 | Feb 2026 → Dec 2030 | B-cell non-Hodgkin lymphoma | University of Utah | Withdrawn | No outcome recorded |
| Phase 1 | NCT05618925 | Aug 2025 → May 2026 overdue | non-Hodgkin lymphoma | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06040918 | Oct 2023 → Sep 2024 | — | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05769569 | Sep 2023 → Jul 2025 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT05245292 | Dec 2022 → Dec 2025 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT04898543 | Jun 2021 → May 2026 overdue | metastatic neoplasm | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04340596 | May 2021 → Jun 2026 overdue | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04808908 | Apr 2021 → Jul 2022 | AIDS | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT04385849 | Jul 2020 | COVID-19 | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04290546 | Jul 2020 → Sep 2024 | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03899480 | May 2019 → Apr 2021 | HIV infectious disease, immunodeficiency disease | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT02890758 | May 2018 → Jun 2021 | Ewing sarcoma, Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +6 | Brenda Cooper, MD | Completed | No outcome recorded |
| Phase 1 | NCT03381586 | Dec 2017 → Mar 2018 | — | Altor BioScience | Completed | No outcome recorded |
| Phase 1 | NCT02689453 | Jan 2017 → Jun 2021 | T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02559674 | Jul 2016 → Feb 2018 | pancreatic neoplasm | Altor BioScience | Completed | No outcome recorded |
| Phase 1 | NCT02191098 | Jun 2015 → Sep 2019 | HIV infectious disease | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT02099539 | Oct 2014 → Jun 2018 | refractory plasma cell neoplasm | Altor BioScience | Terminated | No outcome recorded |
| Phase 1 | NCT01946789 | May 2014 → Aug 2017 | cancer | Altor BioScience | Completed | No outcome recorded |
| Phase 1 | NCT01385423 | Sep 2011 → Mar 2015 | acute myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT00528489 | Oct 2007 → Jan 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/230 trials | ||||||
| Phase 1/2 | NCT05642195 | Jul 2026 → Dec 2033 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1/2 | NCT07355205 | Jul 2026 → Jul 2032 expected | non-small cell lung carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06253494 | May 2024 → Dec 2026 expected | endometrial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06149481 | Mar 2024 → Oct 2027 expected | colorectal cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04247282 | Jun 2020 → Aug 2021 | head and neck cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT04144335 | Jan → Dec 2020 | AIDS | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03563157 | Sep 2018 → Apr 2019 | colorectal cancer | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03647423 | Aug 2018 → Aug 2020 | chordoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169777 | Aug 2018 → Jan 2019 | colorectal cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03586869 | Jul 2018 → Apr 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03563170 | May 2018 → Aug 2019 | hepatocellular carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03493945 | May 2018 → Oct 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03169738 | Feb 2018 → Jan 2019 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03387111 | Jan 2018 → Apr 2019 | squamous cell carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03387098 | Dec 2017 → Sep 2018 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03175666 | Dec 2017 → Jan 2019 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03197584 | Dec 2017 → Feb 2019 | ovarian carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169790 | Dec 2017 → Jan 2019 | non-Hodgkin lymphoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03167164 | Dec 2017 → Jan 2019 | cutaneous neuroendocrine carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169764 | Dec 2017 → Jan 2019 | head and neck squamous cell carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03197571 | Dec 2017 → Jan 2019 | urothelial carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03329248 | Nov 2017 → Aug 2018 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03136406 | Aug → Nov 2017 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03127098 | Jun → Dec 2017 | breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm +2 | NantCell, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02523469 | Jan 2016 → Feb 2023 | non-small cell lung carcinoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1/2 | NCT02384954 | Apr 2015 → Dec 2020 | indolent B-cell non-Hodgkin lymphoma | Altor BioScience | Terminated | No outcome recorded |
| Phase 1/2 | NCT01898793 | Aug 2014 → Dec 2021 | acute myeloid leukemia | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT02138734 | Jul 2014 → Sep 2026 expected | non-invasive bladder urothelial carcinoma | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01885897 | Nov 2013 → Jul 2019 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome +1 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT01369888 | May 2011 → May 2014 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 235 trials | ||||||
| Phase 2 | NCT07574541 | Jul 2026 → Jun 2027 expected | adenocarcinoma, prostate cancer | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07686380 | Jul 2026 → Jan 2029 expected | prostate carcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07628062 | Jul 2026 → Dec 2030 expected | oropharynx squamous cell carcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07578558 | Jul 2026 → Aug 2027 expected | immunodeficiency disease, infectious disease with sepsis, lymphopenia | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07492888 | Apr → Nov 2026 | adult acute respiratory distress syndrome, infectious disease with sepsis, lymphopenia, pneumonia | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT07477366 | Apr 2026 → Dec 2027 expected | indolent B-cell non-Hodgkin lymphoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06765902 | Dec 2025 → Jan 2031 | prostate cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT06765954 | Dec 2025 → Jan 2031 | prostate cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT07108036 | Nov 2025 → Oct 2026 expected | long COVID-19 | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07085338 | Nov 2025 → Feb 2028 expected | neuroblastoma | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06829823 | Nov 2025 → Nov 2026 expected | non-invasive bladder urothelial carcinoma | ImmunityBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06161545 | Sep 2025 → Dec 2026 expected | head and neck squamous cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07123727 | Sep 2025 → Jul 2026 overdue | long COVID-19 | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07145164 | Aug 2025 → Dec 2027 expected | HIV infectious disease | Michael Peluso, MD | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06710288 | Nov 2024 → May 2027 expected | refractory malignant neoplasm | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06061809 | Aug 2024 → Dec 2029 expected | glioblastoma | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05445882 | Apr 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT05419011 | May 2023 → Jul 2027 expected | Lynch syndrome, colorectal carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04847466 | Dec 2021 → Dec 2025 | gastroesophageal cancer, head and neck squamous cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT05007769 | Oct 2021 → Apr 2024 | non-small cell lung carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT04505501 | Mar 2021 → Jun 2025 overdue | HIV infectious disease | Thai Red Cross AIDS Research Centre | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04491955 | Sep 2020 → Oct 2022 | colorectal cancer, small intestine cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04390399 | Jul 2020 → Oct 2025 overdue | malignant pancreatic neoplasm | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03853317 | Feb 2020 → Sep 2021 | cutaneous neuroendocrine carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03228667 | Dec 2018 → Aug 2029 expected | cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma, gastric cancer +8 | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03365661 | Oct 2018 → Jan 2023 | acute myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT03554109 | Sep 2018 → Jun 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03563144 | Aug 2018 → Dec 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03574649 | Jun → Aug 2018 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03054909 | Sep 2017 → Feb 2022 | fallopian tube cancer, primary peritoneal carcinoma, uterine adnexa cancer | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT03050216 | May 2017 → Dec 2019 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02989844 | Apr 2017 → Mar 2022 | acute myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02782546 | Jan 2017 → Oct 2025 overdue | acute myeloid leukemia | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02395822 | Oct 2015 → Dec 2016 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT02465957 | Sep 2015 → Mar 2018 | cutaneous neuroendocrine carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03022825 | Jun 2017 → Oct 2024 overdue | urinary bladder cancer | ImmunityBio, Inc. | Active not recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07524257 | May 2026 → May 2029 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07551544 | May 2026 → May 2032 | non-invasive bladder urothelial carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07492875 | Apr 2026 → Apr 2029 | acute respiratory distress syndrome, immunodeficiency disease, infectious disease with sepsis, lymphopenia +1 | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT06745908 | Oct 2025 → Sep 2028 expected | non-small cell lung carcinoma | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03520686 | May 2018 → Oct 2025 | non-small cell lung carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06956547 | — | lymphopenia | ImmunityBio, Inc. | Available | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07410676 Background | Feb 2026 → Dec 2028 expected | breast cancer, colorectal cancer, cutaneous melanoma, esophageal cancer +9 | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04927884 Background | Sep 2021 → Sep 2022 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03167177 Background | Dec 2017 → Jan 2019 | melanoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03003728 Background | Nov 2019 → Jul 2020 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | ImmunityBio, Inc. | ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer immunitybio.com ↗ |
| 2026-05-22 | ImmunityBio, Inc. | ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS immunitybio.com ↗ |
| 2026-05-19 | ImmunityBio, Inc. | ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 immunitybio.com ↗ |
| 2026-05-18 | ImmunityBio, Inc. | ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 immunitybio.com ↗ |
| 2026-04-21 | ImmunityBio, Inc. | ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership immunitybio.com ↗ |
| 2026-03-26 | ImmunityBio, Inc. | ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 immunitybio.com ↗ |
| 2026-03-20 | ImmunityBio, Inc. | ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors immunitybio.com ↗ |
| 2026-03-17 | ImmunityBio, Inc. | ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease immunitybio.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 106 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-803 | “N-803 is an interleukin 15 (IL-15)/interleukin 15 receptor (IL-15R) alpha super agonist complex that can enhance both natural killer (NK) cell and T cell anti-tumor activity...” NCT04247282 ↗51“a single infusion of haploidentical related donor NK cells was given plus either IL-2 or N-803 (an IL-15 superagonist)” PMID 38207119 ↗ May 2024 “plus an IL-15 superagonist complex, N-803, dosed at 6 mcg/kg, subcutaneously (SC) at week 1” NCT05245292 ↗ “N-803 subcutaneously (SubQ) administered on day 1 of each 21-day cycle” NCT07049432 ↗ “Nogapendekin alfa inbakicept (NAI, also known as N-803, ANKTIVA):” NCT03520686 ↗ “Given nogapendekin alfa inbakicept (N-803) SC” NCT05419011 ↗ “Nogapendekin Alfa Inbakicept (N803)” NCT07488884 ↗ |
| Known as | also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803 | “also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803” NCT03853317 ↗ |
| Known as | ALT-803 | “A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab,...” NCT03647423 ↗34“nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex” NCT05618925 ↗ “N-803 formerly known as Alt-803” NCT02989844 ↗ “N-803, also known as ALT-803” NCT04491955 ↗ |
| Known as | ANKTIVA | “This is a summary of two studies that looked at the safety and effectiveness of a potential new treatment, N-803 (Anktiva), in combination with a standard treatment bacillus...” PMID 38953850 ↗ Jul 20244“Nogapendekin alfa inbakicept (NAI, also known as N-803, ANKTIVA):” NCT03520686 ↗ “N-803 (Anktiva)” NCT04491955 ↗ |
| Known as | IL-15 | “N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and...” NCT07145164 ↗6“Drug: Interleukin-15 (IL-15) Low-dose IL-15 given after NK cell infusion to support NK cell survival dose used in NK protocols: 6 MIU per dose” NCT07410676 ↗ |
| Known as | IL-15N72D:IL-15RαSu/IgG1 Fc complex | “recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]” NCT03574649 ↗1“also known as IL15N72D:IL-15RαSu/IgG1 Fc complex” NCT03169738 ↗ |
| Known as | Interleukin-15 | “N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and...” NCT07145164 ↗1“Drug: Interleukin-15 (IL-15) Low-dose IL-15 given after NK cell infusion to support NK cell survival dose used in NK protocols: 6 MIU per dose” NCT07410676 ↗ |
| Known as | NAI | “Nogapendekin alfa inbakicept (NAI, also known as N-803, ANKTIVA):” NCT03520686 ↗6“IL-15 receptor superagonist nogapendekin-alfa-inbakicept (NAI)” PMID 42238576 ↗ May 2026 “neoadjuvant therapy of nogapendekin alfa inbakicept (NAI) SC” NCT07488884 ↗ “nogapendekin alfa inbakicept (NAI) plus chemoimmunotherapy” NCT07524257 ↗ “Nogapendekin Alfa Inbakicept (NAI)” NCT07628062 ↗ “Nogapendekin alfa inbakicept (NAI)” NCT07578558 ↗ “Nogapendekin alfa inbakicept (NAI)” NCT07492875 ↗ |
| Known as | nogapendekin alfa inbakicept | “N-803 (Nogapendekin Alfa Inbakicept): A soluble complex consisting of a modified human interleukin-15 (IL-15) variant bound to a human IL-15 receptor alpha subunit/human...” NCT06765902 ↗14“N-803 (nogapendekin alfa inbakicept): A soluble complex of an IL-15 variant bound to a human IL-15 receptor alpha subunit/human IgG1 Fc fusion protein.” NCT06765954 ↗ “nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex” NCT05618925 ↗ “Nogapendekin alfa inbakicept (NAI, also known as N-803, ANKTIVA):” NCT03520686 ↗ “Given nogapendekin alfa inbakicept (N-803) SC” NCT05419011 ↗ |
| Known as | recombinant human IL-15 | “To evaluate whether IL-15 potentiates ADCC in humans, we conducted a phase 1 single-center study of recombinant human IL-15 and alemtuzumab in patients with CD52-positive...” PMID 35475910 ↗ Feb 2023 |
| Known as | recombinant human interleukin-15 | “Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 |
| Known as | rhIL-15 | “Forty-two patients received either intravenous (IV) (NCT01385423) or subcutaneous (SC) (NCT02395822) recombinant human IL-15 (rhIL-15) after lymphodepleting chemotherapy and...” PMID 31266741 ↗ Jul 20192“Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 “Intravenous Recombinant Human IL-15 (rhIL-15)” NCT01385423 ↗ |
| Action | Activate | “Preclinical studies with both HIV and SIV suggest that the drug has potential to reduce virus reservoirs by activating virus from latency and enhancing effector function.” PMID 35102335 ↗ Jan 2022 |
| Modality | Protein / enzyme biologic | “recombinant human IL-15” NCT01369888 ↗ |
| Route | Other | “Group 1 will receive an injection of PENNVAX-B combined with 0.8 mg IL-15 in each deltoid or placebo.” NCT00528489 ↗ |